BMRN - BioMarin Pharmaceutical Inc.
88.05 0.00 (0.00%)
After hours: 4:07PM EDT
| Previous Close | 90.78 |
| Open | 90.25 |
| Bid | 87.01 x 1100 |
| Ask | 90.82 x 1000 |
| Day's Range | 87.96 - 90.83 |
| 52 Week Range | 75.81 - 106.74 |
| Volume | 962,198 |
| Avg. Volume | 957,330 |
| Market Cap | 15.706B |
| Beta (3Y Monthly) | 1.36 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.44 |
| Earnings Date | Apr 23, 2019 - Apr 29, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 119.87 |
Market Realist•3 hours agoAnalysts Are Mostly Positive on BioMarin Pharmaceutical in March
How Major Rare Disease Pharma Stocks Are Positioned in March(Continued from Prior Part)Analysts’ recommendations and target priceWall Street analysts expect a potential upside of 32.04% for BioMarin Pharmaceutical (BMRN) based on the stock’s
- American City Business Journals•2 days ago
S.F. hotel demand bubbles over, spilling out into the rest of the Bay Area
Even in development-averse Marin, new hotel proposals are being stuffed into the Bay Area pipeline in an effort to meet accelerating demand.
- Zacks•4 days ago
New Strong Sell Stocks for March 18th
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today
- Markit•10 days ago
See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.
Biomarin Pharmaceutical Inc NASDAQ/NGS:BMRNView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is low for BMRN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding BMRN totaled $2.02 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Simply Wall St.•14 days ago
Did BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Insiders Sell Shares?
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that there are more than a few examplesRead More...
- Zacks•15 days ago
New Strong Sell Stocks for March 7th
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today
- PR Newswire•16 days ago
BioMarin to Participate in Cowen and Company 39th Annual Health Care Conference on March 12 in Boston
SAN RAFAEL, Calif. , March 6, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at the Cowen ...
- American City Business Journals•17 days ago
The $200K Club: Broadcom joins these Bay Area tech companies paying a typical employee top dollar
A handful of Silicon Valley's largest technology companies, including Facebook and Broadcom, pay their median employee more than double the region's per capita income.
- Barrons.com•21 days ago
Why Big Pharma Is Diving Into Gene Therapy
Emerging revolutionary treatments promise possible cures for diseases like hemophilia and muscular dystrophy—and opportunities for investors
- PR Newswire•21 days ago
BioMarin Receives Positive CHMP Opinion in Europe for Palynziq® (pegvaliase Injection) for Treatment of Patients with Phenylketonuria (PKU) Aged 16 and Older
SAN RAFAEL, Calif., March 1, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion for the company's Marketing Authorization Application (MAA) for Palynziq® (pegvaliase) Injection to reduce blood phenylalanine (Phe) concentrations in patients with phenylketonuria (PKU) aged 16 and older, who have inadequate blood Phe control (blood Phe levels greater than 600 micromol/L) despite prior management with available treatment options. In addition, the CHMP noted that the data collected in the Phase 3 trial and extension study was suggestive of an improvement in inattention and mood symptoms.
- Zacks•22 days ago
Sarepta (SRPT) Q4 Earnings Lag Estimates, Exondys 51 Sales Up
Sarepta (SRPT) misses estimates for both earnings and sales in fourth-quarter 2018. However, Exondys 51 performs well on strong demand.
- Motley Fool•24 days ago
BioMarin Revenue Slips, but Big Picture Looks Dandy
Lumpy sales hurt the orphan-drug maker's fourth quarter, but overall growth is still on track.
- PR Newswire•24 days ago
Behind the Seizure™ Program Expansion Helps Speed the Diagnosis of Genetic Epilepsy in Younger Children Experiencing Unprovoked Seizures
SAN FRANCISCO, Feb. 26, 2019 /PRNewswire/ -- As Rare Disease Day focuses attention on the challenges of diagnosing rare, often genetic conditions, BioMarin Pharmaceutical Inc. (BMRN), Invitae Corporation (NVTA), Stoke Therapeutics and Xenon Pharmaceuticals (XENE) today announced the expansion of Behind the Seizure, an innovative, cross-company collaboration that aims to provide faster diagnosis for young children with epilepsy. Previously available to patients ages 2-4 years, the program will expand eligibility to make no-cost genetic testing available for healthcare providers to order for children who have had an unprovoked seizure from birth up to age five (0 to 60 months).
- Motley Fool•24 days ago
2 More Gene Therapy Stocks on Big Pharma's Buyout Radar
Roche's big step into the gene-editing space will spark interest for these two stocks.
- Benzinga•25 days ago
Sell-Side Picks Top Gene Therapy Takeout Candidates Following Spark Therapeutics Deal
Roche Holdings AG Basel ADR (OTC: RHHBY )'s announcement regarding an agreement to acquire gene therapy company Spark Therapeutics Inc (NASDAQ: ONCE ) has sparked a rally in the latter's shares. The Analysts ...
- Investing.com•25 days ago
MarketPulse: Roche's Bumper Deal for Spark Therapeutics Boosts Healthcare Stocks
Investing.com – Swiss-based Roche Holding's bumper offer to acquire Spark Therapeutics on Monday propped up the healthcare sector and fueled speculation on Wall Street that more merger activity is in the pipeline for gene therapy stocks.
- Thomson Reuters StreetEvents•26 days ago
Edited Transcript of BMRN earnings conference call or presentation 21-Feb-19 9:30pm GMT
Q4 2018 Biomarin Pharmaceutical Inc Earnings Call
GuruFocus.com•26 days agoBiogen, BioMarin, Lilly and Bristol-Myers Could Be in Crosshairs of Acquirers
Merck (MRK) shares have been on a roll the past year, up nearly 50% to more than $80 in the past year. In a recent article in FiercePharma, Morningstar analysts said that U.S.-based companies may have to go the acquisition route to increase their high-value pipelines. Warning! GuruFocus has detected 6 Warning Signs with MRK.
- Investor's Business Daily•28 days ago
Can This Biotech Stock Redeem Its Sales Lag With A Strong Gene Therapy?
BioMarin Pharmaceutical stock slipped Friday after the biotech late Thursday reported lagging fourth-quarter revenue. The company said its newest drug cannibalized sales of another.
Motley Fool•28 days agoBioMarin Pharmaceutical Inc. (BMRN) Q4 2018 Earnings Conference Call Transcript
BMRN earnings call for the period ending December 31, 2018.
- Zacks•28 days ago
BioMarin (BMRN) Q4 Earnings & Sales Miss, Shares Decline
BioMarin (BMRN) misses estimates for earnings and revenues in the fourth quarter. Shares decline in after-hours trading.
- Benzinga•28 days ago
The Daily Biotech Pulse: BioMarin Slips On Earnings, TherapeuticsMD Posts In-Line Results, Orchard To Present Immunodeficiency Drug Data
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 21.) Eli Lilly And Co (NYSE: LLY ) Gossamer ...
- Associated Press•29 days ago
BioMarin: 4Q Earnings Snapshot
The San Rafael, California-based company said it had a loss of 3 cents per share. Losses, adjusted for one-time gains and costs, were 6 cents per share. The results missed Wall Street expectations. The ...
- PR Newswire•29 days ago
BioMarin Announces Full Year and Fourth Quarter 2018 Results
- Total Revenues for 2018 Grow 14% Year-over-Year to $1.5 Billion - As of February 15, 2019, 335 U.S. Commercial Patients Receiving Treatment with Palynziq® - In Europe, CHMP Opinion for Palynziq Anticipated ...
